Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10316248" target="_blank" >RIV/00216208:11130/15:10316248 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10316248
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1510665" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1510665</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1510665" target="_blank" >10.1056/NEJMoa1510665</a>
Alternative languages
Result language
angličtina
Original language name
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Original language description
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one ortwo regimens of antiangiogenic therapy were randomly assigned (in a 1: 1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1)
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
373
Issue of the periodical within the volume
19
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1803-1813
UT code for WoS article
000364144000004
EID of the result in the Scopus database
2-s2.0-84946607195